GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sun Biomedical Ltd (ASX:SBN) » Definitions » Operating Margin %

Sun Biomedical (ASX:SBN) Operating Margin % : -5,085.71% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Sun Biomedical Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Sun Biomedical's Operating Income for the six months ended in Dec. 2023 was A$-6.76 Mil. Sun Biomedical's Revenue for the six months ended in Dec. 2023 was A$0.13 Mil. Therefore, Sun Biomedical's Operating Margin % for the quarter that ended in Dec. 2023 was -5,085.71%.

The historical rank and industry rank for Sun Biomedical's Operating Margin % or its related term are showing as below:

ASX:SBN' s Operating Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -14984.21


ASX:SBN's Operating Margin % is ranked worse than
92.99% of 1027 companies
in the Biotechnology industry
Industry Median: -172 vs ASX:SBN: -14984.21

Sun Biomedical's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Sun Biomedical's Operating Income for the six months ended in Dec. 2023 was A$-6.76 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was A$-19.93 Mil.

Warning Sign:

Dimerix Ltd has never been profitable in the past 3 years. It lost money every year.


Sun Biomedical Operating Margin % Historical Data

The historical data trend for Sun Biomedical's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Biomedical Operating Margin % Chart

Sun Biomedical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sun Biomedical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -35,770.37 - -5,085.71

Competitive Comparison of Sun Biomedical's Operating Margin %

For the Biotechnology subindustry, Sun Biomedical's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Biomedical's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sun Biomedical's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Sun Biomedical's Operating Margin % falls into.



Sun Biomedical Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Sun Biomedical's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-22.823 / 0
= %

Sun Biomedical's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-6.764 / 0.133
=-5,085.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sun Biomedical  (ASX:SBN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Sun Biomedical Operating Margin % Related Terms

Thank you for viewing the detailed overview of Sun Biomedical's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sun Biomedical (ASX:SBN) Business Description

Traded in Other Exchanges
Address
425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Sun Biomedical (ASX:SBN) Headlines

No Headlines